OPPORTUNITIES AND PROSPECTS FOR INCORPORATING A THIRD DRUG TO THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C

Abstract

In order to evaluate the efficiency and safety of using the drug Ingaron in treatment ofpatients with chronic hepatitis C (CHC) an open, randomized, control comparative study has been performed. We examined of 132 CHC patients aged from 18 to 58 years. All patients were selected into 3 groups depending on the type of therapy. The following drugs: Ribavirin, Alfarona, Ingaron were included in regimens of therapy. The course of the disease in examined CHC patients was characterized by mild clinical symptoms, the presence of the expressed cytolytic syndrome more than in half of the patients (50.8%), high levels of «viral load» in 61.6% of patients with the establishment of a direct correlation between high ALT and viremia levels (r=+0,67). The average level of «viral load» in patients infected with no-1 genotype of hepatitis C, at the start of therapy was 1,4 times higher than in those with genotype 1, amounting to 1,8 x 106 and 1,3 x 106 IU/ml, respectively. Patients infected with HCV genotype 1 and receiving therapy with Ingaron for 24 and 12 weeks, achieved sustained viral response in 65,0% and 80,0% of cases whereas patients infected with «no 1» genotype - in 73,9%, and 84,6% of cases, respectively. At the same time, in patients from the control group the sustained viral response was observed only in 56,0% and 60,0% of cases (1 and «no 1» genotypes, respectively). The inclusion of Ingaron into the classical medical regimen was accompanied by a reduction in the incidence of adverse reactions during treatment.

Keywords

chronic hepatitis C / interferon-alpha / interferon-gamma / Ingaron / Alfarona

References

[1] Блюм Х.Е. Гепатит С: современное состояние проблемы. Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2005; 1: 20-25.

[2] Дуданова О.П. Распространенность генотипов HCV и особенности течения хронического гепатита С в зависимости от генотипа вируса. Гастроэнтерология Санкт-Петербурга. 2006; 49-50.

[3] Онищенко ГГ Проблемы инфекционных заболеваний и пути их решения. Вестник Российской АМН. 2008; 1: 35-41.

[4] Онищенко Г.Г., Шахгильдян И.В., Михайлов М.И. Распространение вирусных гепатитов как угроза национальной безопасности. Микробиология, эпидемиология и иммунология. 2003; 4: 93-9.

[5] Lusida M., Nagano-Fujii M., Nidon C. Correlation between mulations in the interferon sensitivity - determining region of NS5A protein and viral load of hepatitis С virus subtypes 1b, 1c, and 2a. J. Clin. Microbiol. 2001; 39: 3858-64.

[6] Лобзин Ю.В., Жданов К.В., Волжанин В.М. Вирусные гепатиты (клиника, диагностика, лечение). СПб. 2004; 183.

[7] Луцкий А.А. Клинико-лабораторная и морфологическая характеристика естественного течения и прогноз хронической HCV-инфекции. Автореф. дисс. СПб.; 2009; 22.

[8] Kaygusuz I., Ozturk A. Effects of interferon-alpha2b on hearing. International J. Audiology. 2004; 8: 438-41.

[9] Pawlotsky J. The nature of interferon-alpha resistance in hepatitis С virus infection. Current Opinion in Infectious Diseases. 2003; 16: 587-92.

[10] Киселев О.И., Ершов Ф.И., Деева Э.Г. Интерферон-гамма: новый цитокин в клинической практике «Ингарон». М., 2007.

[11] Balan V., Rosati M., Anderson M., Rakela J. Successful treatment with novel triple drug combination consisting of interferon-gamma, interferon alfacon-1, and ribavirin in a nonresponder HCV patient to pegylated interferon therapy. Digestive Diseases and Sciences. 2006; 51(5): 956-9.

[12] Ершов Ф.И., Киселев О.И. Интерфероны и их индукторы (от молекул до лекарств). М., “Гэотар-Медиа”. 2005.

RIGHTS & PERMISSIONS

Eco-vector